Jagbir Singh
About Jagbir Singh
Jagbir Singh serves as the Director of Pre-Clinical Development at Precision NanoSystems Inc. in Vancouver, British Columbia, where he focuses on designing studies for lipid-based nanoparticulate formulations in cancer treatment.
Current Role at Precision NanoSystems
Jagbir Singh serves as the Director of Pre-Clinical Development at Precision NanoSystems Inc. since 2015. In this role, he is responsible for designing pre-clinical studies that evaluate the efficacy of lipid-based nanoparticulate formulations in combination with various anti-cancer drugs. His work involves utilizing animal tumor models to assess treatment effectiveness. Additionally, he evaluates pharmacokinetics and biodistribution of nanotherapeutics following intravenous administration, contributing to advancements in cancer treatment.
Education and Academic Background
Jagbir Singh completed his Ph.D. in Pharmaceutical Sciences at the University of Saskatchewan from 2008 to 2013. During this period, he also worked as a Teaching Assistant at the university. Prior to this, he earned an M. Pharmacy from Birla Institute of Technology and Science, Pilani, from 2004 to 2006, and a B.(Hons.) Pharmacy from the same institution from 2000 to 2004. His educational background has equipped him with a strong foundation in drug delivery systems.
Previous Work Experience
Before his current position, Jagbir Singh gained diverse experience in the pharmaceutical industry. He interned at Strides Arcolab Limited in 2006, focusing on Intellectual Property for five months in Bangalore, India. He also worked as a Senior Research Associate at Evalueserve from 2006 to 2008 in Gurgaon, India. His experience includes a postdoctoral fellowship at BC Cancer Agency from 2013 to 2015, where he further developed his expertise in cancer research.
Research Contributions and Innovations
Jagbir Singh co-invented lipid-based nanoparticulate formulations of hydroxychloroquine, which have been filed for a provisional US patent. His research focuses on the design and development of novel liposomal formulations aimed at targeting metastatic breast cancer and pancreatic cancer. This work is significant in the field of oncology, as it seeks to enhance the effectiveness of cancer therapies through innovative drug delivery methods.